{
  "doc_id": "19",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "盘点降糖药物的中国指南/共识(上)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "盘点降糖药物的中国指南/共识(上)",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": [],
          "sentence_en": "Review of China's guidelines/consensus on hypoglycemic drugs (Part 1)"
        }
      ],
      "paragraph_en": "Review of China's guidelines/consensus on hypoglycemic drugs (Part 1)"
    },
    {
      "paragraph_id": "1",
      "paragraph": "降糖药物大多基于纠正导致血糖升高的两个主要病理生理改变，即胰岛素抵抗和胰岛素分泌受损。根据作用机制的不同，降糖药可分为：促进胰岛素分泌为主要作用的药物，包括磺脲类、格列奈类、二肽基肽酶-4(DPP-4) 抑制剂、胰高血糖素样肽-1(GLP-1) 受体激动剂或胰岛素替代药物(即外源性胰岛素制剂)；通过其他机制降低血糖的药物，包括双胍类、噻唑烷二酮类、α-糖苷酶抑制剂、钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂。下面我们将逐类盘点近几年发布的相关指南或共识，如存在更新版，则仅讨论最新版本。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降糖药物大多基于纠正导致血糖升高的两个主要病理生理改变，即胰岛素抵抗和胰岛素分泌受损。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T1",
              "entity": "胰岛素分泌受损",
              "entity_type": "Pathogenesis",
              "start_idx": 35,
              "end_idx": 42,
              "entity_en": "Impaired insulin secretion"
            },
            {
              "entity_id": "T2",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T3",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Elevated"
            }
          ],
          "relations": [],
          "sentence_en": "Most glucose-lowering drugs are based on correcting the two main pathophysiological changes that lead to elevated blood sugar, namely insulin resistance and impaired insulin secretion."
        },
        {
          "sentence_id": "1",
          "sentence": "根据作用机制的不同，降糖药可分为：促进胰岛素分泌为主要作用的药物，包括磺脲类、格列奈类、二肽基肽酶-4(DPP-4) 抑制剂、胰高血糖素样肽-1(GLP-1) 受体激动剂或胰岛素替代药物(即外源性胰岛素制剂)；通过其他机制降低血糖的药物，包括双胍类、噻唑烷二酮类、α-糖苷酶抑制剂、钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂。",
          "start_idx": 43,
          "end_idx": 208,
          "entities": [
            {
              "entity_id": "T4",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T5",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T6",
              "entity": "二肽基肽酶-4(DPP-4) 抑制剂",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 62,
              "entity_en": "Dipeptidyl peptidase-4 (DPP-4) inhibitors"
            },
            {
              "entity_id": "T7",
              "entity": "胰高血糖素样肽-1(GLP-1) 受体激动剂",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 85,
              "entity_en": "Glucagon-like peptide-1 (GLP-1) receptor agonists"
            },
            {
              "entity_id": "T8",
              "entity": "胰岛素替代药物(即外源性胰岛素制剂)",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 104,
              "entity_en": "Insulin replacement drugs (i.e. exogenous insulin preparations)"
            },
            {
              "entity_id": "T9",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "Biguanides"
            },
            {
              "entity_id": "T10",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 131,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T11",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 140,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T12",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 164,
              "entity_en": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "According to the different mechanisms of action, hypoglycemic drugs can be divided into: drugs that mainly promote insulin secretion, including sulfonylureas, glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists or insulin replacement drugs (i.e. exogenous insulin preparations); drugs that lower blood sugar through other mechanisms, including biguanides, thiazolidinediones, α-glucosidase inhibitors, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors."
        },
        {
          "sentence_id": "2",
          "sentence": "下面我们将逐类盘点近几年发布的相关指南或共识，如存在更新版，则仅讨论最新版本。",
          "start_idx": 208,
          "end_idx": 247,
          "entities": [],
          "relations": [],
          "sentence_en": "Below we will review the relevant guidelines or consensus released in recent years one by one. If there is an updated version, only the latest version will be discussed."
        },
        {
          "sentence_id": "3",
          "sentence": " ",
          "start_idx": 247,
          "end_idx": 248,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Most glucose-lowering drugs are based on correcting the two main pathophysiological changes that lead to elevated blood sugar, namely insulin resistance and impaired insulin secretion. According to the different mechanisms of action, glucose-lowering drugs can be divided into: drugs that promote insulin secretion as the main effect, including sulfonylureas, glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists or insulin replacement drugs (i.e. exogenous insulin preparations); drugs that lower blood sugar through other mechanisms, including biguanides, thiazolidinediones, α-glucosidase inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors. Below we will review the relevant guidelines or consensus published in recent years, and if there is an updated version, only the latest version will be discussed."
    },
    {
      "paragraph_id": "2",
      "paragraph": "二甲双胍(资料来源：《二甲双胍临床应用专家共识(2016年版)》) ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍(资料来源：《二甲双胍临床应用专家共识(2016年版)》) ",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T13",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T14",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Metformin (Source: Expert Consensus on the Clinical Application of Metformin (2016 Edition))"
        }
      ],
      "paragraph_en": "Metformin (Source: Expert Consensus on the Clinical Application of Metformin (2016 Edition))"
    },
    {
      "paragraph_id": "3",
      "paragraph": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。",
          "start_idx": 0,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T15",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T16",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T17",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T18",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T19",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T20",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T21",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T19",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R2",
              "head_entity_id": "T19",
              "tail_entity_id": "T18"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T21",
              "tail_entity_id": "T18"
            }
          ],
          "sentence_en": "Metformin is an old drug that has been used clinically for 60 years. It has experienced ups and downs. Currently, major diabetes guidelines at home and abroad recognize its core position and recommend that both overweight and normal-weight type 2 diabetes patients should use metformin for treatment from the beginning unless there are contraindications or intolerance, and metformin should be included in combination treatment plans."
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 120,
          "end_idx": 121,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Metformin is an old drug that has been used clinically for 60 years. It has experienced several ups and downs. Currently, major diabetes guidelines at home and abroad recognize its core position and recommend that both overweight and normal-weight type 2 diabetes patients should use metformin for treatment from the beginning unless there are contraindications or intolerance, and metformin should be included in combination treatment plans."
    },
    {
      "paragraph_id": "4",
      "paragraph": "作用机制 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "作用机制 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Mechanism of action"
        }
      ],
      "paragraph_en": "Mechanism of action"
    },
    {
      "paragraph_id": "5",
      "paragraph": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。近年来研究者们更是发现二甲双胍可能具有改善肠道茵群、抗癌、抗衰老等更多”神奇“的作用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。",
          "start_idx": 0,
          "end_idx": 139,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T23",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R4",
              "head_entity_id": "T22",
              "tail_entity_id": "T23"
            }
          ],
          "sentence_en": "The main mechanisms by which metformin improves hyperglycemia include: (1) acting on the liver, inhibiting gluconeogenesis and reducing hepatic glucose output; (2) acting on peripheral tissues (muscle, fat), improving muscle glycogen synthesis, reducing free fatty acids, improving insulin sensitivity, and increasing glucose uptake and utilization; (3) acting on the intestine, inhibiting glucose uptake by intestinal wall cells and increasing glucagon-like peptide-1 (GLP-1) levels."
        },
        {
          "sentence_id": "1",
          "sentence": "近年来研究者们更是发现二甲双胍可能具有改善肠道茵群、抗癌、抗衰老等更多”神奇“的作用。",
          "start_idx": 139,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T24",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "In recent years, researchers have discovered that metformin may have more \"magical\" effects, such as improving intestinal flora, anti-cancer, and anti-aging."
        }
      ],
      "paragraph_en": "The main mechanisms of metformin in improving hyperglycemia include: (1) acting on the liver, inhibiting gluconeogenesis and reducing liver glucose output; (2) acting on peripheral tissues (muscle, fat), improving muscle glycogen synthesis, reducing free fatty acids, improving insulin sensitivity, and increasing glucose uptake and utilization; (3) acting on the intestine, inhibiting intestinal wall cells from taking up glucose and increasing glucagon-like peptide-1 (GLP-1) levels. In recent years, researchers have found that metformin may have more \"magical\" effects such as improving intestinal flora, anti-cancer, and anti-aging."
    },
    {
      "paragraph_id": "6",
      "paragraph": "国内的多位内分泌、药学专家于2014年发布了第一版《二甲双胍临床应用专家共识》，基于这两年涌现的新证据，该共识于2016年进行了更新，从使用时机、剂量与疗效、安全性、特殊人群的使用以及降糖外作用等多个方面给出了指导建议。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "国内的多位内分泌、药学专家于2014年发布了第一版《二甲双胍临床应用专家共识》，基于这两年涌现的新证据，该共识于2016年进行了更新，从使用时机、剂量与疗效、安全性、特殊人群的使用以及降糖外作用等多个方面给出了指导建议。",
          "start_idx": 0,
          "end_idx": 110,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "In 2014, a number of domestic endocrinology and pharmacy experts released the first edition of \"Expert Consensus on the Clinical Application of Metformin\". Based on new evidence emerging in the past two years, the consensus was updated in 2016, providing guidance and suggestions on timing of use, dosage and efficacy, safety, use in special populations, and effects other than hypoglycemic effects."
        }
      ],
      "paragraph_en": "In 2014, a number of domestic endocrinology and pharmacy experts released the first edition of \"Expert Consensus on the Clinical Application of Metformin\". Based on new evidence emerging in the past two years, the consensus was updated in 2016, providing guidance and suggestions on timing of use, dosage and efficacy, safety, use in special populations, and effects other than hypoglycemic effects."
    },
    {
      "paragraph_id": "7",
      "paragraph": "适用人群 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Target Group"
        }
      ],
      "paragraph_en": "Target Group"
    },
    {
      "paragraph_id": "8",
      "paragraph": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T27",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T28",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T29",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T30",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R5",
              "head_entity_id": "T26",
              "tail_entity_id": "T27"
            }
          ],
          "sentence_en": "It should be said that metformin is a true full-course treatment drug for diabetes, from diabetes prevention to prediabetes to all stages of diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 45,
          "end_idx": 46,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "It should be said that metformin is a true full-course treatment drug for diabetes, from diabetes prevention to prediabetes to all stages of diabetes."
    },
    {
      "paragraph_id": "9",
      "paragraph": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。\"",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。",
          "start_idx": 0,
          "end_idx": 463,
          "entities": [
            {
              "entity_id": "T31",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T32",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T33",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 33,
              "end_idx": 41,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T34",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "oral"
            },
            {
              "entity_id": "T35",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "oral"
            },
            {
              "entity_id": "T36",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 100,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T37",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T38",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 156,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T39",
              "entity": "减轻体重",
              "entity_type": "ADE",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Lose weight"
            },
            {
              "entity_id": "T40",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 191,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T41",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 259,
              "end_idx": 263,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T42",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 266,
              "end_idx": 271,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T43",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 299,
              "end_idx": 302,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T44",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 321,
              "end_idx": 326,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T45",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 336,
              "end_idx": 338,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T46",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 339,
              "end_idx": 341,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T47",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 342,
              "end_idx": 347,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T48",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 350,
              "end_idx": 354,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T49",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 370,
              "end_idx": 374,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T50",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 380,
              "end_idx": 382,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T51",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 383,
              "end_idx": 385,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T52",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 386,
              "end_idx": 391,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T53",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 409,
              "end_idx": 413,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T54",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 435,
              "end_idx": 440,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T55",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 266,
              "end_idx": 268,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T56",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 321,
              "end_idx": 323,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T57",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 342,
              "end_idx": 344,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T58",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 386,
              "end_idx": 388,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T59",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 435,
              "end_idx": 437,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T60",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T61",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 114,
              "end_idx": 116,
              "entity_en": "oral"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T32",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R7",
              "head_entity_id": "T60",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R8",
              "head_entity_id": "T33",
              "tail_entity_id": "T32"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R9",
              "head_entity_id": "T39",
              "tail_entity_id": "T38"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R10",
              "head_entity_id": "T41",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T55",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R12",
              "head_entity_id": "T56",
              "tail_entity_id": "T44"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R13",
              "head_entity_id": "T48",
              "tail_entity_id": "T45"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T48",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R15",
              "head_entity_id": "T48",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R16",
              "head_entity_id": "T57",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R17",
              "head_entity_id": "T49",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T49",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R19",
              "head_entity_id": "T49",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T58",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R21",
              "head_entity_id": "T59",
              "tail_entity_id": "T54"
            }
          ],
          "sentence_en": "(1) First-line and full-course medication for type 2 diabetes: In horizontal comparisons, the best effective dose (2000 mg/day) of metformin has a stronger glucose-lowering effect than other oral glucose-lowering drugs; in longitudinal comparisons, compared with patients who use other oral glucose-lowering drugs as first-line drugs, patients who use metformin as first-line treatment are the last to add a second oral glucose-lowering drug or require combined insulin treatment, and are also least likely to need to adjust their treatment regimen in the future. The \"side effect\" of metformin in reducing weight makes it a \"jack of all trades\" in combination therapy. In addition, metformin also has cardiovascular protective effects, is safe and well tolerated, and is not expensive. With so many benefits, it is no wonder that the consensus makes such a recommendation, and it is the highest level recommendation - if there are no contraindications, metformin is the first-line drug for the treatment of type 2 diabetes and the basic treatment drug in the combination therapy, and should always be retained in the diabetes treatment plan. I remember that in the 2007 edition of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", metformin was only recommended as a first-line drug for overweight or obese type 2 diabetes patients. Subsequent research evidence showed that metformin was equally effective in normal weight/overweight/obese type 2 diabetes patients, and weight was not a determining factor in whether metformin could be used for treatment. Therefore, as early as the 2010 edition of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", recommendations similar to this consensus were given."
        },
        {
          "sentence_id": "1",
          "sentence": "\"",
          "start_idx": 463,
          "end_idx": 464,
          "entities": [],
          "relations": [],
          "sentence_en": "\""
        }
      ],
      "paragraph_en": "(1) First-line and full-course medication for type 2 diabetes: In horizontal comparisons, the best effective dose (2000 mg/day) of metformin has a stronger glucose-lowering effect than other oral glucose-lowering drugs; in longitudinal comparisons, compared with patients who use other oral glucose-lowering drugs as first-line drugs, patients who use metformin as first-line treatment are the last to add a second oral glucose-lowering drug or require combined insulin treatment, and are also least likely to need to adjust their treatment regimen in the future. The \"side effect\" of metformin in reducing weight makes it a \"jack of all trades\" in combination therapy. In addition, metformin also has cardiovascular protective effects, is safe and well tolerated, and is not expensive. With so many benefits, it is no wonder that the consensus makes such a recommendation, and it is the highest level recommendation - if there are no contraindications, metformin is the first-line drug for the treatment of type 2 diabetes and the basic treatment drug in the combination therapy, and should always be retained in the diabetes treatment plan. I remember that in the 2007 edition of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", only overweight or obese patients with type 2 diabetes were recommended to use metformin as the first-line drug. Later research evidence showed that metformin was equally effective in normal-weight/overweight/obese patients with type 2 diabetes, and weight was not a determining factor for whether metformin could be used for treatment. Therefore, as early as the 2010 edition of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", similar recommendations to this consensus were given."
    },
    {
      "paragraph_id": "10",
      "paragraph": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
          "start_idx": 0,
          "end_idx": 348,
          "entities": [
            {
              "entity_id": "T62",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T63",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T64",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T65",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T66",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T67",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 50,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T68",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T69",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T70",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T71",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T72",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 145,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T73",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 164,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T74",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 159,
              "end_idx": 161,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T75",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 171,
              "end_idx": 174,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T76",
              "entity": "空腹血糖受损(IFG)",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 198,
              "entity_en": "Impaired fasting glucose (IFG)"
            },
            {
              "entity_id": "T77",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 206,
              "end_idx": 208,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T78",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 214,
              "end_idx": 218,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T79",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 227,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T80",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 252,
              "end_idx": 254,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T81",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 260,
              "end_idx": 264,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T82",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 269,
              "end_idx": 272,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T83",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 296,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T84",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 307,
              "end_idx": 310,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T85",
              "entity": "糖代谢评估",
              "entity_type": "Test",
              "start_idx": 334,
              "end_idx": 339,
              "entity_en": "Glucose metabolism assessment"
            },
            {
              "entity_id": "T86",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 340,
              "end_idx": 343,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T87",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 178,
              "end_idx": 184,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T88",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 234,
              "end_idx": 240,
              "entity_en": "Lifestyle interventions"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R22",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R23",
              "head_entity_id": "T64",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R24",
              "head_entity_id": "T69",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T71",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R26",
              "head_entity_id": "T74",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R27",
              "head_entity_id": "T87",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R28",
              "head_entity_id": "T78",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R29",
              "head_entity_id": "T78",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R30",
              "head_entity_id": "T88",
              "tail_entity_id": "T79"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T80",
              "tail_entity_id": "T79"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R32",
              "head_entity_id": "T81",
              "tail_entity_id": "T82"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T83",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R34",
              "head_entity_id": "T85",
              "tail_entity_id": "T86"
            }
          ],
          "sentence_en": "(2) Medication for the prevention of type 2 diabetes: Metformin is the first drug proven to prevent or delay the onset of diabetes. It can effectively reduce the risk of type 2 diabetes in people with prediabetes and has good tolerability and long-term effectiveness. However, in my country, the prevention of diabetes is not yet an indication for metformin, so the consensus cannot give clear recommendations. However, the consensus mentioned that based on the results of large-scale studies in various countries, the International Diabetes Federation (IDF) 2012 Global Guidelines for Type 2 Diabetes recommends that the best way to prevent diabetes is to start with lifestyle intervention; for obese people with impaired fasting glucose (IFG) and those aged <60 years, metformin intervention can be given; and it is recommended that people with prediabetes should start with lifestyle intervention. For patients whose lifestyle cannot effectively control blood sugar, metformin can effectively prevent diabetes (this is an off-label use of the drug - note from this journal). Patients who receive metformin intervention should be limited to prediabetic individuals who are willing to prevent diabetes, have good treatment compliance, and have the conditions to undergo regular glucose metabolism assessments as prescribed by their doctors."
        }
      ],
      "paragraph_en": "(2) Medication for the prevention of type 2 diabetes: Metformin is the first drug proven to prevent or delay the onset of diabetes. It can effectively reduce the risk of type 2 diabetes in people with prediabetes and has good tolerability and long-term effectiveness. However, in my country, the prevention of diabetes is not yet an indication for metformin, so the consensus cannot give clear recommendations. However, the consensus mentioned that based on the results of large-scale studies in various countries, the International Diabetes Federation (IDF) 2012 Global Guidelines for Type 2 Diabetes recommends that the best way to prevent diabetes is to start with lifestyle intervention; for obese people with impaired fasting glucose (IFG) and those aged <60 years, metformin intervention can be given; and it is recommended that people with prediabetes should start with lifestyle intervention. For patients whose lifestyle cannot effectively control blood sugar, metformin can effectively prevent diabetes (this is an off-label use of the drug - note from this journal). Patients who receive metformin intervention should be limited to prediabetic individuals who are willing to prevent diabetes, have good treatment compliance, and have the conditions to undergo regular glucose metabolism assessments as prescribed by their doctors."
    },
    {
      "paragraph_id": "11",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Clinical Usage"
        }
      ],
      "paragraph_en": "Clinical Usage"
    },
    {
      "paragraph_id": "12",
      "paragraph": "(1)剂型选择：目前，国内单一成分的二甲双胍制剂包括普通片(250毫克/片、500毫克/片或850毫克/片)、缓释片或胶囊(500毫克/片或500毫克/胶囊)、肠溶片或胶囊(250毫克/片或250毫克/胶囊)等；复方制剂则包括二甲双胍与磺脲类、吡格列酮或DPP一4抑制剂组成的复方制剂。该共识指出：①各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放，肠溶片从胃排空到肠道后崩解释放，缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放，肠溶胶囊在肠道内溶出、释放；②普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之，因而每种制剂给药后血药浓度峰值、达峰时间、半衰期等参数存在一定差异，多剂量给药后的达稳时间也不一致；③缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；④合格的药物制剂，在相同的给药剂量下，各种剂型问应具有生物等效性；⑤不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)剂型选择：目前，国内单一成分的二甲双胍制剂包括普通片(250毫克/片、500毫克/片或850毫克/片)、缓释片或胶囊(500毫克/片或500毫克/胶囊)、肠溶片或胶囊(250毫克/片或250毫克/胶囊)等；复方制剂则包括二甲双胍与磺脲类、吡格列酮或DPP一4抑制剂组成的复方制剂。",
          "start_idx": 0,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T89",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T90",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T91",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 126,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T92",
              "entity": "DPP一4抑制剂",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 135,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T94",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "(1) Dosage form selection: Currently, domestic single-ingredient metformin preparations include regular tablets (250 mg/tablet, 500 mg/tablet or 850 mg/tablet), sustained-release tablets or capsules (500 mg/tablet or 500 mg/capsule), enteric-coated tablets or capsules (250 mg/tablet or 250 mg/capsule), etc.; combination preparations include combination preparations of metformin with sulfonylureas, pioglitazone or DPP-4 inhibitors."
        },
        {
          "sentence_id": "1",
          "sentence": "该共识指出：①各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放，肠溶片从胃排空到肠道后崩解释放，缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放，肠溶胶囊在肠道内溶出、释放；②普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之，因而每种制剂给药后血药浓度峰值、达峰时间、半衰期等参数存在一定差异，多剂量给药后的达稳时间也不一致；③缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；④合格的药物制剂，在相同的给药剂量下，各种剂型问应具有生物等效性；⑤不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
          "start_idx": 143,
          "end_idx": 435,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 215,
              "end_idx": 220,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T95",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 143,
              "end_idx": 147,
              "entity_en": "Blood concentration"
            }
          ],
          "relations": [],
          "sentence_en": "The consensus points out that: ① The main difference between various dosage forms lies in the different dissolution and release behaviors of the drugs in the preparations after administration. Ordinary tablets disintegrate and release in the stomach, enteric-coated tablets disintegrate and release after the stomach is emptied into the intestines, sustained-release tablets and sustained-release capsules dissolve and release slowly in the gastrointestinal tract, and enteric-coated capsules dissolve and release in the intestines; ② Ordinary tablets dissolve faster in the stomach, followed by enteric-coated tablets and enteric-coated capsules, and then sustained-release tablets. Therefore, there are certain differences in parameters such as peak blood drug concentration, peak time, half-life, etc. after administration of each preparation, and the stable time after multiple doses is also inconsistent; ③ Compared with ordinary tablets, sustained-release tablets/capsules and enteric-coated tablets/capsules can reduce gastrointestinal reactions after administration and improve patients' medication compliance; ④ For qualified drug preparations, various dosage forms should have bioequivalence at the same dosage; ⑤ Whether the clinical efficacy of different dosage forms is consistent still needs more clinical research to confirm."
        }
      ],
      "paragraph_en": "(1) Dosage form selection: Currently, domestic single-ingredient metformin preparations include regular tablets (250 mg/tablet, 500 mg/tablet or 850 mg/tablet), sustained-release tablets or capsules (500 mg/tablet or 500 mg/capsule), enteric-coated tablets or capsules (250 mg/tablet or 250 mg/capsule), etc.; combination preparations include combination preparations of metformin with sulfonylureas, pioglitazone or DPP-4 inhibitors. The consensus points out that: ① The main difference between various dosage forms lies in the different dissolution and release behaviors of the drugs in the preparations after administration. Ordinary tablets disintegrate and release in the stomach, enteric-coated tablets disintegrate and release after the stomach is emptied into the intestines, sustained-release tablets and sustained-release capsules dissolve and release slowly in the gastrointestinal tract, and enteric-coated capsules dissolve and release in the intestines; ② Ordinary tablets dissolve faster in the stomach, followed by enteric-coated tablets and enteric-coated capsules, and then sustained-release tablets. Therefore, there are certain differences in parameters such as peak blood drug concentration, peak time, half-life, etc. after administration of each preparation, and the stable time after multiple doses is also inconsistent; ③ Compared with ordinary tablets, sustained-release tablets/capsules and enteric-coated tablets/capsules can reduce gastrointestinal reactions after administration and improve patients' medication compliance; ④ For qualified drug preparations, various dosage forms should have bioequivalence at the same dosage; ⑤ Whether the clinical efficacy of different dosage forms is consistent still needs more clinical research to confirm."
    },
    {
      "paragraph_id": "13",
      "paragraph": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。大家看看是不是自己的二甲双胍用量远没有达到这个标准。②调量剂量调整遵循“小剂量起始，逐渐加量”的原则，开始时每日用量不超1000毫克，1~2周后加量至最大有效剂量2000毫克/天或最大耐受剂量。考虑药物的临床疗效及从患者依从性，可采用简化的剂量方案，建议起始500毫克，2次/天，如无明显胃肠道不良反应，随后可逐至1000，2次/天。③服法可在进餐时或餐后立即服用，缓释剂型1次/天，晚餐时或餐后立即服用。根据患者状况，当每日用量达到1500毫克后，可分为2~3次服用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。",
          "start_idx": 0,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T96",
              "entity": "500~2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 19,
              "end_idx": 31,
              "entity_en": "500–2000 mg/day"
            },
            {
              "entity_id": "T97",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T98",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 72,
              "end_idx": 77,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T99",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 94,
              "end_idx": 98,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T100",
              "entity": "500毫克/天",
              "entity_type": "Amount",
              "start_idx": 106,
              "end_idx": 113,
              "entity_en": "500 mg/day"
            },
            {
              "entity_id": "T101",
              "entity": "2550毫克/天",
              "entity_type": "Amount",
              "start_idx": 124,
              "end_idx": 132,
              "entity_en": "2550 mg/day"
            },
            {
              "entity_id": "T102",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 140,
              "end_idx": 148,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T111",
              "entity": "每日用量达到1000豪克",
              "entity_type": "Amount",
              "start_idx": 58,
              "end_idx": 70,
              "entity_en": "Daily dosage up to 1000 mg"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R35",
              "head_entity_id": "T96",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R36",
              "head_entity_id": "T111",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T98",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R38",
              "head_entity_id": "T100",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R39",
              "head_entity_id": "T101",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R40",
              "head_entity_id": "T102",
              "tail_entity_id": "T99"
            }
          ],
          "sentence_en": "(2) Usage: ① Dosage Clinical studies have shown that within the dosage range of 500-2000 mg/day, the hypoglycemic effect of metformin increases with increasing dosage, and when the daily dosage reaches 1000 mg, gastrointestinal reactions do not increase with increasing dosage. The consensus recommends that the minimum effective dose of metformin is 500 mg/day, the maximum dose for adults is 2550 mg/day, and the optimal effective dose is 2000 mg/day."
        },
        {
          "sentence_id": "1",
          "sentence": "大家看看是不是自己的二甲双胍用量远没有达到这个标准。",
          "start_idx": 149,
          "end_idx": 175,
          "entities": [
            {
              "entity_id": "T103",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Everyone should check to see if their metformin dosage is far from this standard."
        },
        {
          "sentence_id": "2",
          "sentence": "②调量剂量调整遵循“小剂量起始，逐渐加量”的原则，开始时每日用量不超1000毫克，1~2周后加量至最大有效剂量2000毫克/天或最大耐受剂量。",
          "start_idx": 175,
          "end_idx": 246,
          "entities": [
            {
              "entity_id": "T104",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 55,
              "end_idx": 63,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T112",
              "entity": "每日用量不超1000毫克",
              "entity_type": "Amount",
              "start_idx": 28,
              "end_idx": 40,
              "entity_en": "Daily dosage should not exceed 1000 mg"
            }
          ],
          "relations": [],
          "sentence_en": "② Dose adjustment should follow the principle of \"starting with a small dose and gradually increasing the dose\". The initial daily dose should not exceed 1000 mg. After 1 to 2 weeks, the dose should be increased to the maximum effective dose of 2000 mg/day or the maximum tolerated dose."
        },
        {
          "sentence_id": "3",
          "sentence": "考虑药物的临床疗效及从患者依从性，可采用简化的剂量方案，建议起始500毫克，2次/天，如无明显胃肠道不良反应，随后可逐至1000，2次/天。",
          "start_idx": 246,
          "end_idx": 316,
          "entities": [
            {
              "entity_id": "T105",
              "entity": "500毫克",
              "entity_type": "Amount",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "500 mg"
            },
            {
              "entity_id": "T106",
              "entity": "2次/天",
              "entity_type": "Frequency",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "2 times/day"
            },
            {
              "entity_id": "T107",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 54,
              "entity_en": "Gastrointestinal adverse reactions"
            },
            {
              "entity_id": "T108",
              "entity": "1000",
              "entity_type": "Amount",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "1000"
            },
            {
              "entity_id": "T109",
              "entity": "2次/天",
              "entity_type": "Frequency",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "2 times/day"
            }
          ],
          "relations": [],
          "sentence_en": "Considering the clinical efficacy of the drug and patient compliance, a simplified dosage regimen can be adopted. It is recommended to start with 500 mg, twice a day. If there are no obvious gastrointestinal adverse reactions, the dosage can be gradually increased to 1000 mg, twice a day."
        },
        {
          "sentence_id": "4",
          "sentence": "③服法可在进餐时或餐后立即服用，缓释剂型1次/天，晚餐时或餐后立即服用。",
          "start_idx": 316,
          "end_idx": 352,
          "entities": [
            {
              "entity_id": "T110",
              "entity": "1次/天",
              "entity_type": "Frequency",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "1 time/day"
            }
          ],
          "relations": [],
          "sentence_en": "③Dosage: It can be taken during or immediately after meals. The sustained-release dosage form can be taken once a day during or immediately after dinner."
        },
        {
          "sentence_id": "5",
          "sentence": "根据患者状况，当每日用量达到1500毫克后，可分为2~3次服用。",
          "start_idx": 352,
          "end_idx": 384,
          "entities": [
            {
              "entity_id": "T113",
              "entity": "每日用量达到1500毫克",
              "entity_type": "Amount",
              "start_idx": 8,
              "end_idx": 20,
              "entity_en": "Daily dosage up to 1500 mg"
            }
          ],
          "relations": [],
          "sentence_en": "Depending on the patient's condition, when the daily dosage reaches 1500 mg, it can be taken in 2 to 3 times."
        }
      ],
      "paragraph_en": "(2) Usage: ① Dosage Clinical studies have shown that within the dosage range of 500-2000 mg/day, the hypoglycemic effect of metformin increases with increasing dosage, and when the daily dosage reaches 1000 mg, the gastrointestinal reaction does not increase with increasing dosage. The consensus recommends that the minimum dose of metformin for onset of efficacy is 500 mg/day, the maximum dose for adults is 2550 mg/day, and the optimal effective dose is 2000 mg/day. Please check whether your metformin dosage is far from this standard. ② Adjustment of dosage The dosage adjustment follows the principle of \"starting with a small dose and gradually increasing the dosage\". The daily dosage should not exceed 1000 mg at the beginning, and the dosage should be increased to the maximum effective dose of 2000 mg/day or the maximum tolerated dose after 1-2 weeks. Considering the clinical efficacy of the drug and patient compliance, a simplified dosage regimen can be adopted. It is recommended to start with 500 mg, twice a day. If there are no obvious gastrointestinal adverse reactions, it can be gradually increased to 1000 mg, twice a day. ③ Dosage: It can be taken during or immediately after meals. The sustained-release dosage form can be taken once a day during or immediately after dinner. Depending on the patient's condition, when the daily dosage reaches 1500 mg, it can be taken in 2 to 3 times."
    },
    {
      "paragraph_id": "14",
      "paragraph": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。",
          "start_idx": 0,
          "end_idx": 99,
          "entities": [
            {
              "entity_id": "T114",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T115",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 71,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T116",
              "entity": "胃肠不适",
              "entity_type": "ADE",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "Gastrointestinal discomfort"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T116",
              "tail_entity_id": "T114"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            }
          ],
          "sentence_en": "(3) Combination therapy: To summarize this part of the consensus, metformin can be used in combination with various currently available hypoglycemic drugs in clinical practice, and it can also reduce the side effects of some hypoglycemic drugs (except α-glucosidase inhibitors, the combination of the two may increase gastrointestinal discomfort), thereby achieving the effect of leveraging the strengths and avoiding the weaknesses."
        }
      ],
      "paragraph_en": "(3) Combination therapy: To summarize this part of the consensus, metformin can be used in combination with various currently available hypoglycemic drugs in clinical practice, and it can also reduce the side effects of some hypoglycemic drugs (except α-glucosidase inhibitors, the combination of the two may increase gastrointestinal discomfort), thereby achieving the effect of leveraging the strengths and avoiding the weaknesses."
    },
    {
      "paragraph_id": "15",
      "paragraph": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。",
          "start_idx": 0,
          "end_idx": 696,
          "entities": [
            {
              "entity_id": "T117",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T118",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 42,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T119",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T120",
              "entity": "心衰",
              "entity_type": "ADE",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T121",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 68,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T122",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 66,
              "end_idx": 67,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T123",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T124",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 93,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T125",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 91,
              "end_idx": 92,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T126",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 104,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T127",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T128",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T129",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T130",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T131",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T132",
              "entity": "充血性心衰",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T133",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 161,
              "end_idx": 162,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T134",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T135",
              "entity": "慢性心衰",
              "entity_type": "Disease",
              "start_idx": 182,
              "end_idx": 186,
              "entity_en": "Chronic heart failure"
            },
            {
              "entity_id": "T136",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T137",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 247,
              "end_idx": 251,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T138",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 255,
              "end_idx": 260,
              "entity_en": "Monitoring renal function"
            },
            {
              "entity_id": "T139",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 262,
              "end_idx": 266,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T140",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 276,
              "end_idx": 281,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T141",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 276,
              "end_idx": 278,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T142",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 295,
              "end_idx": 303,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T143",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 333,
              "end_idx": 337,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T144",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 340,
              "end_idx": 345,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T145",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 370,
              "end_idx": 374,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T146",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 384,
              "end_idx": 388,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T147",
              "entity": "肝脏毒性",
              "entity_type": "ADE",
              "start_idx": 396,
              "end_idx": 400,
              "entity_en": "Hepatotoxicity"
            },
            {
              "entity_id": "T148",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 404,
              "end_idx": 409,
              "entity_en": "Serum transaminases"
            },
            {
              "entity_id": "T149",
              "entity": "超过3倍正常上限",
              "entity_type": "Test_Value",
              "start_idx": 409,
              "end_idx": 417,
              "entity_en": "More than 3 times the normal upper limit"
            },
            {
              "entity_id": "T150",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 419,
              "end_idx": 421,
              "entity_en": "serious"
            },
            {
              "entity_id": "T151",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 421,
              "end_idx": 426,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T152",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 421,
              "end_idx": 422,
              "entity_en": "liver"
            },
            {
              "entity_id": "T153",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 438,
              "end_idx": 443,
              "entity_en": "Serum transaminases"
            },
            {
              "entity_id": "T154",
              "entity": "轻度升高",
              "entity_type": "Test_Value",
              "start_idx": 443,
              "end_idx": 447,
              "entity_en": "Mildly elevated"
            },
            {
              "entity_id": "T155",
              "entity": "监测肝功能",
              "entity_type": "Test",
              "start_idx": 454,
              "end_idx": 459,
              "entity_en": "Monitoring liver function"
            },
            {
              "entity_id": "T156",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 461,
              "end_idx": 465,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T157",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 487,
              "end_idx": 491,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T158",
              "entity": "伤肾",
              "entity_type": "ADE",
              "start_idx": 491,
              "end_idx": 493,
              "entity_en": "Kidney damage"
            },
            {
              "entity_id": "T159",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 521,
              "end_idx": 525,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T160",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 533,
              "end_idx": 536,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T161",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 536,
              "end_idx": 541,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T162",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 536,
              "end_idx": 537,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T163",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 545,
              "end_idx": 547,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T164",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 547,
              "end_idx": 552,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T165",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 547,
              "end_idx": 548,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T166",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 584,
              "end_idx": 586,
              "entity_en": "Imaging"
            },
            {
              "entity_id": "T167",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 591,
              "end_idx": 595,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T168",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 599,
              "end_idx": 602,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T169",
              "entity": "肾功能异常",
              "entity_type": "Disease",
              "start_idx": 636,
              "end_idx": 641,
              "entity_en": "Abnormal renal function"
            },
            {
              "entity_id": "T170",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 636,
              "end_idx": 637,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T171",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 645,
              "end_idx": 648,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T172",
              "entity": "全身麻醉",
              "entity_type": "Operation",
              "start_idx": 649,
              "end_idx": 653,
              "entity_en": "General anesthesia"
            },
            {
              "entity_id": "T173",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 663,
              "end_idx": 667,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T174",
              "entity": "复查肾功能",
              "entity_type": "Test",
              "start_idx": 682,
              "end_idx": 687,
              "entity_en": "Review renal function"
            },
            {
              "entity_id": "T175",
              "entity": "复查肾功能",
              "entity_type": "Test",
              "start_idx": 621,
              "end_idx": 626,
              "entity_en": "Review renal function"
            },
            {
              "entity_id": "T176",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 39,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T177",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 185,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R43",
              "head_entity_id": "T176",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R44",
              "head_entity_id": "T122",
              "tail_entity_id": "T121"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R45",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R46",
              "head_entity_id": "T127",
              "tail_entity_id": "T126"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R47",
              "head_entity_id": "T131",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R48",
              "head_entity_id": "T177",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T139",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R50",
              "head_entity_id": "T142",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R52",
              "head_entity_id": "T143",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R53",
              "head_entity_id": "T152",
              "tail_entity_id": "T151"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T159",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R55",
              "head_entity_id": "T162",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R56",
              "head_entity_id": "T165",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R57",
              "head_entity_id": "T170",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T171",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R59",
              "head_entity_id": "T172",
              "tail_entity_id": "T169"
            }
          ],
          "sentence_en": "(4) Special circumstances: ① Although the contraindications in the metformin instructions list congestive heart failure that requires drug treatment, studies have shown that metformin itself does not cause heart failure, nor does it have adverse effects on patients with heart failure. On the contrary, it may even reduce the risk of heart failure and death in diabetic patients and improve the survival rate of diabetic patients with heart failure. Therefore, the American Diabetes Association (ADA) diabetes guidelines point out that if renal function is normal, metformin can be used in patients with stable congestive heart failure; the European version of the metformin instructions even lists contraindications for chronic heart failure. ② Age is also not a contraindication for the use of metformin, but it depends on the patient's renal function. As renal function gradually declines with age, elderly patients need to monitor their renal function regularly when using metformin. ③Metformin can be used for children and adolescents with type 2 diabetes aged 10 years and above, and the maximum dose does not exceed 2000 mg/day. It is not recommended for children under 10 years old. ④Although many international academic organizations recommend that metformin can be used in patients with gestational diabetes, due to the lack of domestic evidence, my country's drug regulatory authorities have not yet approved metformin for pregnant women. ⑤Although metformin is not metabolized by the liver and has no liver toxicity, it is recommended that patients with serum transaminase exceeding 3 times the upper limit of normal or severe liver dysfunction avoid using metformin. Patients with mild elevation of serum transaminase should closely monitor liver function when using it. ⑥Metformin itself does not affect renal function. With the popularization of education, the public's misunderstanding of metformin's damage to the kidneys has been generally corrected. In recent years, major domestic and foreign guidelines have expanded the scope of use of metformin to patients with mild to moderate renal insufficiency, but patients with moderate renal insufficiency should reduce the dosage and stop using drugs for the treatment of nausea, vomiting and dehydration. ⑦ Patients with normal renal function do not need to stop taking metformin before angiography, but should stop taking it for 48 to 72 hours under the guidance of a doctor after using contrast agents. They can continue taking the medicine after renal function is normal. Patients with abnormal renal function should stop taking metformin 48 hours before using contrast agents and general anesthesia, and then stop taking it for 48 to 72 hours. They can continue taking the medicine after renal function is normal."
        }
      ],
      "paragraph_en": "(4) Special circumstances: ① Although the contraindications in the metformin instructions list congestive heart failure that requires drug treatment, studies have shown that metformin itself does not cause heart failure, nor does it have adverse effects on patients with heart failure. On the contrary, it may even reduce the risk of heart failure and death in diabetic patients and improve the survival rate of diabetic patients with heart failure. Therefore, the American Diabetes Association (ADA) diabetes guidelines point out that if renal function is normal, metformin can be used in patients with stable congestive heart failure; the European version of the metformin instructions even lists contraindications for chronic heart failure. ② Age is also not a contraindication for the use of metformin, but it depends on the patient's renal function. As renal function gradually declines with age, elderly patients need to monitor their renal function regularly when using metformin. ③Metformin can be used for children and adolescents with type 2 diabetes aged 10 years and above, and the maximum dose does not exceed 2000 mg/day. It is not recommended for children under 10 years old. ④Although many international academic organizations recommend that metformin can be used in patients with gestational diabetes, due to the lack of domestic evidence, my country's drug regulatory authorities have not yet approved metformin for pregnant women. ⑤Although metformin is not metabolized by the liver and has no liver toxicity, it is recommended that patients with serum transaminase exceeding 3 times the upper limit of normal or severe liver dysfunction avoid using metformin. Patients with mild elevation of serum transaminase should closely monitor liver function when using it. ⑥Metformin itself does not affect renal function. With the popularization of education, the public's misunderstanding of metformin's damage to the kidneys has been generally corrected. In recent years, major domestic and foreign guidelines have expanded the scope of use of metformin to patients with mild to moderate renal insufficiency, but patients with moderate renal insufficiency should reduce the dosage and stop using drugs for the treatment of nausea, vomiting and dehydration. ⑦ Patients with normal renal function do not need to stop taking metformin before angiography, but should stop taking it for 48 to 72 hours under the guidance of a doctor after using contrast agents. They can continue taking the medicine after renal function is normal. Patients with abnormal renal function should stop taking metformin 48 hours before using contrast agents and general anesthesia, and then stop taking it for 48 to 72 hours. They can continue taking the medicine after renal function is normal."
    },
    {
      "paragraph_id": "16",
      "paragraph": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。④树脂类药物，如苏合香、血竭、乳香等中药与二甲双胍合用会减少其吸收。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。",
          "start_idx": 0,
          "end_idx": 230,
          "entities": [
            {
              "entity_id": "T178",
              "entity": "氨氯吡咪",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Amiloride"
            },
            {
              "entity_id": "T179",
              "entity": "地高辛",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "Digoxin"
            },
            {
              "entity_id": "T180",
              "entity": "吗啡",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "morphine"
            },
            {
              "entity_id": "T181",
              "entity": "普鲁卡因胺",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Procainamide"
            },
            {
              "entity_id": "T182",
              "entity": "奎尼丁",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "Quinidine"
            },
            {
              "entity_id": "T183",
              "entity": "奎宁",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Quinine"
            },
            {
              "entity_id": "T184",
              "entity": "雷尼替丁",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Ranitidine"
            },
            {
              "entity_id": "T185",
              "entity": "氨苯蝶啶",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "Triamterene"
            },
            {
              "entity_id": "T186",
              "entity": "甲氧苄氨嘧啶",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 52,
              "entity_en": "Trimethoprim"
            },
            {
              "entity_id": "T187",
              "entity": "万古霉素",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Vancomycin"
            },
            {
              "entity_id": "T188",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T189",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 84,
              "entity_en": "Monitoring blood sugar"
            },
            {
              "entity_id": "T190",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T191",
              "entity": "噻嗪类药物",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 112,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T192",
              "entity": "利尿剂",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "Diuretics"
            },
            {
              "entity_id": "T193",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 124,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T194",
              "entity": "吩噻嗪",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 128,
              "entity_en": "Phenothiazines"
            },
            {
              "entity_id": "T195",
              "entity": "甲状腺制剂",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 134,
              "entity_en": "Thyroid preparations"
            },
            {
              "entity_id": "T196",
              "entity": "雌激素",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 138,
              "entity_en": "Estrogen"
            },
            {
              "entity_id": "T197",
              "entity": "口服避孕药",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "Oral contraceptives"
            },
            {
              "entity_id": "T198",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 139,
              "end_idx": 141,
              "entity_en": "oral"
            },
            {
              "entity_id": "T199",
              "entity": "苯妥英",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 148,
              "entity_en": "Phenytoin"
            },
            {
              "entity_id": "T200",
              "entity": "烟碱酸",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "Nicotinic acid"
            },
            {
              "entity_id": "T201",
              "entity": "拟交感神经药",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 159,
              "entity_en": "Sympathomimetic drugs"
            },
            {
              "entity_id": "T202",
              "entity": "钙离子通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 168,
              "entity_en": "Calcium channel blockers"
            },
            {
              "entity_id": "T203",
              "entity": "异烟肼",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 172,
              "entity_en": "Isoniazid"
            },
            {
              "entity_id": "T204",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 176,
              "end_idx": 178,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T205",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 178,
              "end_idx": 180,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T206",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 189,
              "end_idx": 193,
              "entity_en": "Monitoring blood sugar"
            },
            {
              "entity_id": "T207",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 208,
              "end_idx": 211,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 213,
              "end_idx": 217,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T209",
              "entity": "华法林",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 223,
              "entity_en": "Warfarin"
            },
            {
              "entity_id": "T210",
              "entity": "抗凝血",
              "entity_type": "ADE",
              "start_idx": 224,
              "end_idx": 227,
              "entity_en": "Anticoagulation"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R60",
              "head_entity_id": "T198",
              "tail_entity_id": "T197"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R61",
              "head_entity_id": "T210",
              "tail_entity_id": "T209"
            }
          ],
          "sentence_en": "(5) Drug interactions: ① Drugs such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin can affect renal function or metformin distribution, so it is recommended to closely monitor blood sugar and adjust the dose of metformin and/or other drugs. ② When taking thiazides or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid at the same time, blood sugar should also be closely monitored. After these drugs are discontinued, pay close attention to hypoglycemia. ③ Metformin has the tendency to increase the anticoagulant effect of warfarin."
        },
        {
          "sentence_id": "1",
          "sentence": "④树脂类药物，如苏合香、血竭、乳香等中药与二甲双胍合用会减少其吸收。",
          "start_idx": 230,
          "end_idx": 264,
          "entities": [
            {
              "entity_id": "T211",
              "entity": "苏合香",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "Styrax"
            },
            {
              "entity_id": "T212",
              "entity": "血竭",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "Dragon's Blood"
            },
            {
              "entity_id": "T213",
              "entity": "乳香",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "mastic"
            },
            {
              "entity_id": "T214",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T215",
              "entity": "树脂类药物",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 6,
              "entity_en": "Resin drugs"
            }
          ],
          "relations": [],
          "sentence_en": "④ Resin drugs, such as storax, dragon's blood, frankincense and other traditional Chinese medicines, combined with metformin will reduce their absorption."
        }
      ],
      "paragraph_en": "(5) Drug interactions: ① Drugs such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin can affect renal function or metformin distribution, so it is recommended to closely monitor blood sugar and adjust the dose of metformin and/or other drugs. ② When taking thiazides or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid, which can cause blood sugar to rise, blood sugar should also be closely monitored. After these drugs are discontinued, pay close attention to hypoglycemia. ③ Metformin has the tendency to increase the anticoagulant effect of warfarin. ④ Resin drugs, such as storax, dragon's blood, frankincense and other traditional Chinese medicines, combined with metformin will reduce its absorption."
    },
    {
      "paragraph_id": "17",
      "paragraph": "磺脲类药物(资料来源：《磺脲类药物临床应用专家共识(2016年版)》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物(资料来源：《磺脲类药物临床应用专家共识(2016年版)》)",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T216",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T217",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Sulfonylurea drugs (Source: Expert Consensus on the Clinical Application of Sulfonylurea Drugs (2016 Edition))"
        }
      ],
      "paragraph_en": "Sulfonylurea drugs (Source: Expert Consensus on the Clinical Application of Sulfonylurea Drugs (2016 Edition))"
    },
    {
      "paragraph_id": "18",
      "paragraph": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。基于循证医学证据的进展，2004年版《磺脲类药物临床应用专家共识》在2016年得到更新。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。",
          "start_idx": 0,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T218",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T219",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T220",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T221",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "oral"
            },
            {
              "entity_id": "T222",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T223",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T218",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R63",
              "head_entity_id": "T221",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T223",
              "tail_entity_id": "T222"
            }
          ],
          "sentence_en": "Sulfonylurea drugs have been officially used in the clinical treatment of diabetes for nearly 60 years. They are still one of the most widely used oral hypoglycemic drugs in the treatment of diabetes, and occupy a very important treatment position in domestic and international type 2 diabetes guidelines."
        },
        {
          "sentence_id": "1",
          "sentence": "基于循证医学证据的进展，2004年版《磺脲类药物临床应用专家共识》在2016年得到更新。",
          "start_idx": 79,
          "end_idx": 123,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Based on the progress of evidence-based medicine, the 2004 edition of \"Expert Consensus on the Clinical Application of Sulfonylureas\" was updated in 2016."
        }
      ],
      "paragraph_en": "Sulfonylureas have been used in the clinical treatment of diabetes for nearly 60 years and are still one of the most widely used oral hypoglycemic drugs in the field of diabetes treatment. They also occupy a very important treatment position in the guidelines for type 2 diabetes at home and abroad. Based on the progress of evidence-based medicine, the 2004 edition of the Expert Consensus on the Clinical Application of Sulfonylureas was updated in 2016."
    },
    {
      "paragraph_id": "19",
      "paragraph": "作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "作用机制",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Mechanism of action"
        }
      ],
      "paragraph_en": "Mechanism of action"
    },
    {
      "paragraph_id": "20",
      "paragraph": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。②部分胰岛素增敏作用。试验表明，磺脲类药物可使外周葡萄糖利用率加平均增加近三分之一(29%)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。",
          "start_idx": 0,
          "end_idx": 56,
          "entities": [
            {
              "entity_id": "T225",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T226",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T227",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Glimepiride"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T225",
              "tail_entity_id": "T226"
            }
          ],
          "sentence_en": "The mechanisms by which sulfonylureas improve hyperglycemia include: ① stimulating pancreatic β cells to secrete insulin, among which glimepiride may have a glucose-dependent insulin-secreting effect."
        },
        {
          "sentence_id": "1",
          "sentence": "②部分胰岛素增敏作用。",
          "start_idx": 56,
          "end_idx": 67,
          "entities": [],
          "relations": [],
          "sentence_en": "②Partial insulin sensitizing effect."
        },
        {
          "sentence_id": "2",
          "sentence": "试验表明，磺脲类药物可使外周葡萄糖利用率加平均增加近三分之一(29%)。",
          "start_idx": 67,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Trials have shown that sulfonylureas can increase peripheral glucose utilization by an average of nearly one-third (29%)."
        }
      ],
      "paragraph_en": "The mechanisms of sulfonylurea drugs in improving hyperglycemia include: ① stimulating the secretion of insulin by pancreatic β cells, among which glimepiride may have a glucose-dependent effect of promoting insulin secretion. ② Partial insulin sensitization effect. Experiments have shown that sulfonylurea drugs can increase the peripheral glucose utilization rate by an average of nearly one-third (29%)."
    },
    {
      "paragraph_id": "21",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Target Group"
        }
      ],
      "paragraph_en": "Target Group"
    },
    {
      "paragraph_id": "22",
      "paragraph": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T229",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T230",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T231",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T229",
              "tail_entity_id": "T230"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R67",
              "head_entity_id": "T231",
              "tail_entity_id": "T230"
            }
          ],
          "sentence_en": "Despite the emergence of new glucose-lowering drugs, sulfonylureas are still widely used both at home and abroad due to their rich clinical application experience, definite efficacy and low price. Many domestic and foreign type 2 diabetes guidelines also recommend them as first-line alternatives or second-line glucose-lowering drugs."
        }
      ],
      "paragraph_en": "Despite the emergence of new glucose-lowering drugs, sulfonylureas are still widely used both at home and abroad due to their rich clinical application experience, definite efficacy and low price. Many type 2 diabetes guidelines at home and abroad also recommend them as first-line alternatives or second-line glucose-lowering drugs."
    },
    {
      "paragraph_id": "23",
      "paragraph": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
          "start_idx": 0,
          "end_idx": 151,
          "entities": [
            {
              "entity_id": "T232",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T233",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T234",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 54,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T235",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 80,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T236",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 80,
              "end_idx": 85,
              "entity_en": ">7.5%"
            },
            {
              "entity_id": "T237",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T238",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T239",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 132,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T240",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Metformin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R68",
              "head_entity_id": "T238",
              "tail_entity_id": "T237"
            }
          ],
          "sentence_en": "(1) First-line alternatives: Although metformin is used as a first-line drug, sulfonylureas can be considered as first-line drugs when patients cannot tolerate metformin treatment or have contraindications. The consensus also points out that for newly diagnosed type 2 diabetes patients with glycosylated hemoglobin >7.5%, two glucose-lowering drugs with complementary mechanisms of action can be used in combination. Considering China's national conditions and patient characteristics, sulfonylureas combined with metformin are one of the recommended combination treatment options."
        }
      ],
      "paragraph_en": "(1) First-line alternatives: Although metformin is used as a first-line drug, sulfonylureas can be considered as first-line drugs when patients cannot tolerate metformin treatment or have contraindications. The consensus also points out that for newly diagnosed type 2 diabetes patients with glycosylated hemoglobin >7.5%, two glucose-lowering drugs with complementary mechanisms of action can be used in combination. Considering China's national conditions and patient characteristics, sulfonylureas combined with metformin are one of the recommended combination treatment options."
    },
    {
      "paragraph_id": "24",
      "paragraph": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T241",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T242",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 48,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T243",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T244",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T245",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 81,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T246",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "obesity"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R69",
              "head_entity_id": "T244",
              "tail_entity_id": "T243"
            }
          ],
          "sentence_en": "(2) Second-line medication: When the optimal effective dose of metformin alone cannot control blood sugar to the target, other types of hypoglycemic drugs need to be added, and sulfonylureas are one of the alternatives. It should be pointed out that although sulfonylureas can cause weight gain in patients, overweight or obesity is not a contraindication to their treatment."
        },
        {
          "sentence_id": "1",
          "sentence": "相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。",
          "start_idx": 95,
          "end_idx": 211,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T248",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T249",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T250",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T251",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T252",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 49,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T253",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T254",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T255",
              "entity": "SGLT一2抑制剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 84,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T256",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 108,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T257",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 109,
              "end_idx": 113,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R70",
              "head_entity_id": "T257",
              "tail_entity_id": "T256"
            }
          ],
          "sentence_en": "Compared with traditional sulfonylurea drugs (such as chlorpropamide and glibenclamide), new sulfonylurea drugs (such as glimepiride) and dosage forms (such as gliclazide extended-release tablets) have less impact on patients' weight. In addition, by combining with drugs with weight-reducing effects such as metformin, acarbose, and SGLT-2 inhibitors, the risk of weight gain caused by sulfonylurea drugs can be reduced."
        }
      ],
      "paragraph_en": "(2) Second-line medication: When the optimal effective dose of metformin alone is still unable to control blood sugar to the target, other types of hypoglycemic drugs need to be added, and sulfonylureas are one of the alternatives. It should be pointed out that although sulfonylureas can cause patients to gain weight, being overweight or obese is not a contraindication to their treatment. Compared with traditional sulfonylureas (such as chlorpropamide and glibenclamide), new sulfonylureas (such as glimepiride) and dosage forms (such as gliclazide sustained-release tablets) have less effect on patients' weight, and can be used in combination with drugs that have weight-reducing effects such as metformin, acarbose, and SGLT-2 inhibitors to reduce the risk of weight gain from sulfonylureas."
    },
    {
      "paragraph_id": "25",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Clinical Usage"
        }
      ],
      "paragraph_en": "Clinical Usage"
    },
    {
      "paragraph_id": "26",
      "paragraph": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。早期磺脲类药物甲苯磺丁脲和氯磺丙脲已基本退出临床，目前临床常用的磺脲类药物包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲等。格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短，适用于餐后血糖升高为主的患者；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长，适用于以空腹血糖升高为主的患者或空腹、餐后血糖均高的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。",
          "start_idx": 0,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T258",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T259",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T260",
              "entity": "饮食和运动干预",
              "entity_type": "Treatment",
              "start_idx": 55,
              "end_idx": 62,
              "entity_en": "Diet and exercise interventions"
            },
            {
              "entity_id": "T261",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 72,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R71",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R72",
              "head_entity_id": "T261",
              "tail_entity_id": "T259"
            }
          ],
          "sentence_en": "(1) Drug selection: It is not difficult to see from the hypoglycemic mechanism of sulfonylurea drugs that patients need to have a certain level of pancreatic islet function for them to be effective. Therefore, patients with a short course of diabetes and who can adhere to diet and exercise interventions will have a better effect when using sulfonylurea drugs."
        },
        {
          "sentence_id": "1",
          "sentence": "早期磺脲类药物甲苯磺丁脲和氯磺丙脲已基本退出临床，目前临床常用的磺脲类药物包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲等。",
          "start_idx": 79,
          "end_idx": 144,
          "entities": [
            {
              "entity_id": "T262",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T263",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T264",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T265",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T266",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T267",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T268",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T269",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T270",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Glyburide"
            }
          ],
          "relations": [],
          "sentence_en": "Early sulfonylurea drugs tolbutamide and chlorpropamide have basically been withdrawn from clinical practice. Currently, commonly used sulfonylurea drugs in clinical practice include glimepiride, gliclazide, glipizide, gliquidone, and glibenclamide."
        },
        {
          "sentence_id": "2",
          "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短，适用于餐后血糖升高为主的患者；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长，适用于以空腹血糖升高为主的患者或空腹、餐后血糖均高的患者。",
          "start_idx": 144,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T271",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T272",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T273",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T274",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T275",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T276",
              "entity": "格列吡嗪控释剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 54,
              "entity_en": "Glipizide controlled release"
            },
            {
              "entity_id": "T277",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T278",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 67,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T279",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T280",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T281",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T282",
              "entity": "空腹、餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 110,
              "entity_en": "Fasting and postprandial blood sugar"
            },
            {
              "entity_id": "T283",
              "entity": "均高",
              "entity_type": "Test_Value",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "Average height"
            }
          ],
          "relations": [],
          "sentence_en": "The ordinary dosage forms of gliclazide and glipizide are short-acting preparations with a shorter duration of action, and are suitable for patients with mainly elevated blood sugar after meals. Glimepiride, glipizide controlled-release, gliclazide, gliclazide sustained-release tablets, and glibenclamide are medium- and long-acting preparations with a longer duration of action, and are suitable for patients with mainly elevated fasting blood sugar or patients with high fasting and postprandial blood sugar."
        }
      ],
      "paragraph_en": "(1) Drug selection: It is not difficult to see from the hypoglycemic mechanism of sulfonylurea drugs that patients need to have a certain pancreatic islet function for them to be effective. Therefore, patients with a short course of diabetes and who can adhere to diet and exercise intervention will have better efficacy when using sulfonylurea drugs. The early sulfonylurea drugs tolbutamide and chlorpropamide have basically withdrawn from clinical practice. Currently, the commonly used sulfonylurea drugs in clinical practice include glimepiride, gliclazide, glipizide, gliquidone, and glyburide. Gliquidone and glipizide are short-acting preparations with a short duration of action. They are suitable for patients with mainly elevated blood sugar after meals; glimepiride, glipizide controlled-release preparations, gliclazide, gliclazide sustained-release tablets, and glyburide are medium- and long-acting preparations with a longer duration of action. They are suitable for patients with mainly elevated fasting blood sugar or patients with high fasting and postprandial blood sugar."
    },
    {
      "paragraph_id": "27",
      "paragraph": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。任何一种磺脲类药物的每日用量都不应超过其最大剂量。常用磺脲类药物的用法见表1。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。",
          "start_idx": 0,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T284",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T285",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 42,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T286",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T287",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T288",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T291",
              "entity": "水平越高",
              "entity_type": "Test_Value",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "The higher the level"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R73",
              "head_entity_id": "T286",
              "tail_entity_id": "T287"
            }
          ],
          "sentence_en": "(2) Usage: The hypoglycemic effect of sulfonylureas is dose-dependent within conventional doses, and the higher the patient's initial glycosylated hemoglobin level, the greater the reduction after treatment. Since hypoglycemia is the most common adverse reaction of sulfonylureas, it is advisable to start with a small dose and gradually adjust the dosage according to the results of blood glucose monitoring, generally every 1 to 2 weeks."
        },
        {
          "sentence_id": "1",
          "sentence": "任何一种磺脲类药物的每日用量都不应超过其最大剂量。",
          "start_idx": 113,
          "end_idx": 138,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The maximum daily dose of any sulfonylurea should not be exceeded."
        },
        {
          "sentence_id": "2",
          "sentence": "常用磺脲类药物的用法见表1。",
          "start_idx": 138,
          "end_idx": 152,
          "entities": [
            {
              "entity_id": "T290",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The usage of commonly used sulfonylurea drugs is shown in Table 1."
        }
      ],
      "paragraph_en": "(2) Usage: The hypoglycemic effect of sulfonylureas is dose-dependent within conventional doses, and the higher the patient's initial glycated hemoglobin level, the greater the reduction after treatment. Since hypoglycemia is the most common adverse reaction of sulfonylureas, it is advisable to start with a small dose and gradually adjust the dosage based on blood glucose monitoring results, generally every 1 to 2 weeks. The daily dose of any sulfonylurea drug should not exceed its maximum dose. The usage of commonly used sulfonylurea drugs is shown in Table 1."
    },
    {
      "paragraph_id": "28",
      "paragraph": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T292",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T293",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T294",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T295",
              "entity": "增重",
              "entity_type": "ADE",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T296",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T297",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 85,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T298",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 126,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T299",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T300",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T301",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 148,
              "end_idx": 150,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T302",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 165,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T303",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 172,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T304",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 191,
              "end_idx": 195,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T305",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 196,
              "end_idx": 199,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T306",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T307",
              "entity": "注意饮食和运动量",
              "entity_type": "Treatment",
              "start_idx": 180,
              "end_idx": 188,
              "entity_en": "Pay attention to diet and exercise"
            },
            {
              "entity_id": "T308",
              "entity": "减重",
              "entity_type": "ADE",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "Weight loss"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R74",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R75",
              "head_entity_id": "T295",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R76",
              "head_entity_id": "T301",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R77",
              "head_entity_id": "T302",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T303",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R79",
              "head_entity_id": "T307",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R80",
              "head_entity_id": "T304",
              "tail_entity_id": "T302"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R81",
              "head_entity_id": "T305",
              "tail_entity_id": "T302"
            }
          ],
          "sentence_en": "(3) Combination therapy: Although sulfonylureas can theoretically be used in combination with various hypoglycemic drugs to achieve better hypoglycemic effects, as mentioned earlier, considering the hypoglycemia and weight gain side effects of sulfonylureas, it is more suitable to be used in combination with metformin, α-glucosidase inhibitors and other drugs with low hypoglycemia risk and weight loss effects. It should be pointed out that although sulfonylureas combined with insulin therapy are generally not recommended, patients with type 2 diabetes who still have some secretory function of pancreatic islet cells can consider using sulfonylureas combined with basal insulin therapy, but special attention should be paid to diet and exercise, as well as weight gain and hypoglycemia."
        }
      ],
      "paragraph_en": "(3) Combination therapy: Although sulfonylureas can theoretically be used in combination with various hypoglycemic drugs to achieve better hypoglycemic effects, as mentioned earlier, considering the hypoglycemia and weight gain side effects of sulfonylureas, it is more suitable to be used in combination with metformin, α-glucosidase inhibitors and other drugs with low hypoglycemia risk and weight loss effects. It should be pointed out that although sulfonylureas combined with insulin therapy are generally not recommended, patients with type 2 diabetes who still have some secretory function of pancreatic islet cells can consider using sulfonylureas combined with basal insulin therapy, but special attention should be paid to diet and exercise, as well as weight gain and hypoglycemia."
    },
    {
      "paragraph_id": "29",
      "paragraph": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。④目前，所有磺脲类药物均未被中国食品药品监督管理局(CFDA)批准用于妊娠、儿童和青少年患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。",
          "start_idx": 0,
          "end_idx": 341,
          "entities": [
            {
              "entity_id": "T309",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T310",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T311",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T312",
              "entity": "丙氨酸氨基转移酶(ALT)",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 49,
              "entity_en": "Alanine aminotransferase (ALT)"
            },
            {
              "entity_id": "T313",
              "entity": ">8~10倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 60,
              "entity_en": ">8~10 times the upper limit of reference value"
            },
            {
              "entity_id": "T314",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "ALT"
            },
            {
              "entity_id": "T315",
              "entity": ">3倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 72,
              "entity_en": ">3 times the upper limit of reference value"
            },
            {
              "entity_id": "T316",
              "entity": "血清总胆红素(TBIL)",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 85,
              "entity_en": "Total serum bilirubin (TBIL)"
            },
            {
              "entity_id": "T317",
              "entity": ">2倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 85,
              "end_idx": 93,
              "entity_en": ">2 times the upper limit of reference value"
            },
            {
              "entity_id": "T318",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T319",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 100,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T320",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 97,
              "end_idx": 98,
              "entity_en": "liver"
            },
            {
              "entity_id": "T321",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 109,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T322",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T323",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 112,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T324",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T325",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T326",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 133,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T327",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T328",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 141,
              "end_idx": 143,
              "entity_en": "Mild"
            },
            {
              "entity_id": "T329",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 143,
              "end_idx": 148,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T330",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 143,
              "end_idx": 144,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T331",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T332",
              "entity": "轻、中度",
              "entity_type": "Level",
              "start_idx": 159,
              "end_idx": 163,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T333",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 168,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T334",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 164,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T335",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 209,
              "end_idx": 212,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T336",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 221,
              "end_idx": 224,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T337",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 219,
              "end_idx": 221,
              "entity_en": "serious"
            },
            {
              "entity_id": "T338",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 268,
              "end_idx": 273,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T339",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 278,
              "end_idx": 282,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T340",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 289,
              "end_idx": 294,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T341",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 307,
              "end_idx": 311,
              "entity_en": "Monitoring blood sugar"
            },
            {
              "entity_id": "T342",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 316,
              "end_idx": 318,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T343",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 329,
              "end_idx": 332,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T345",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "liver"
            },
            {
              "entity_id": "T346",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 261,
              "end_idx": 264,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T345",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R83",
              "head_entity_id": "T312",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R84",
              "head_entity_id": "T314",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R85",
              "head_entity_id": "T316",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R86",
              "head_entity_id": "T320",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R87",
              "head_entity_id": "T323",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T325",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R89",
              "head_entity_id": "T326",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R90",
              "head_entity_id": "T327",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R91",
              "head_entity_id": "T330",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T331",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R93",
              "head_entity_id": "T334",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R94",
              "head_entity_id": "T343",
              "tail_entity_id": "T340"
            }
          ],
          "sentence_en": "(4) Special circumstances: ① Currently, all sulfonylurea drug instructions list severe liver dysfunction as a contraindication. Alanine aminotransferase (ALT) > 8 to 10 times the upper limit of the reference value or ALT > 3 times the upper limit of the reference value and serum total bilirubin (TBIL) > 2 times the upper limit of the reference value indicates severe liver damage, and sulfonylurea drugs should be contraindicated. ② Glibenclamide is contraindicated in patients with renal insufficiency. Glipizide, gliclazide, and glimepiride can be used for patients with mild renal insufficiency, and gliclazide can be used for patients with mild to moderate renal insufficiency. Doctors need to determine how to adjust treatment based on renal function, see Table 2. ③ Elderly patients should focus on the hypoglycemia risk of drugs. If they have a history of severe hypoglycemia, a short expected life span, or other serious diseases, it is advisable to choose sulfonylurea drugs with milder hypoglycemic effects, shorter duration of action, and lower hypoglycemia risk, and avoid using gliclazide. Regardless of which sulfonylurea drug is chosen, it should be started at the lowest dose, blood sugar changes should be closely monitored, and the dose should be gradually adjusted to the appropriate dose based on blood sugar to minimize the risk of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "④目前，所有磺脲类药物均未被中国食品药品监督管理局(CFDA)批准用于妊娠、儿童和青少年患者。",
          "start_idx": 341,
          "end_idx": 388,
          "entities": [
            {
              "entity_id": "T344",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "④Currently, all sulfonylurea drugs have not been approved by the China Food and Drug Administration (CFDA) for use in pregnant women, children and adolescent patients."
        }
      ],
      "paragraph_en": "(4) Special circumstances: ① Currently, all sulfonylurea drug instructions list severe liver dysfunction as a contraindication. Alanine aminotransferase (ALT) > 8 to 10 times the upper limit of the reference value or ALT > 3 times the upper limit of the reference value and serum total bilirubin (TBIL) > 2 times the upper limit of the reference value indicates severe liver damage, and sulfonylurea drugs should be contraindicated. ② Glibenclamide is contraindicated in patients with renal insufficiency. Glipizide, gliclazide, and glimepiride can be used for patients with mild renal insufficiency, and gliclazide can be used for patients with mild to moderate renal insufficiency. Doctors need to determine how to adjust treatment based on renal function, see Table 2. ③ Elderly patients should focus on the hypoglycemia risk of drugs. If they have a history of severe hypoglycemia, a short expected life span, or other serious diseases, it is advisable to choose sulfonylurea drugs with milder hypoglycemic effects, shorter duration of action, and lower hypoglycemia risk, and avoid using gliclazide. Regardless of which sulfonylurea drug is chosen, it should be started from the lowest dose, blood sugar changes should be closely monitored, and the dose should be gradually adjusted to the appropriate dose according to blood sugar to minimize the risk of hypoglycemia. ④ Currently, all sulfonylurea drugs have not been approved by the China Food and Drug Administration (CFDA) for use in pregnant women, children, and adolescents."
    }
  ]
}